Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.
Related news for (NERV)
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/21/25 09:00 AM
- Biotech Booms, as Innovation-Driven Rally Gains Steam
- MoBot alert highlights: NASDAQ: PSTV, NASDAQ: NERV, NASDAQ: SPWR, NASDAQ: BYND, NASDAQ: TNON (10/21/25 08:00 AM)
- Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
- 24/7 Market News Snapshot 21 October, 2025 – Minerva Neurosciences, Inc (NASDAQ:NERV)
